


LEUKERAN® (chlorambucil) 2-mg Sugar-coated Tablets

WARNING: LEUKERAN (chlorambucil) can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility (see WARNINGS and PRECAUTIONS).

DESCRIPTION: LEUKERAN (chlorambucil) was first synthesized by Everett et al.¹ It is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases. Chlorambucil is known chemically as 4-[bis(2-chlorethyl)amino]benzenebutanoic acid and has the following structural formula:



Chlorambucil hydrolyzes in water and has a pKa of 5.8.

LEUKERAN (chlorambucil) is available in tablet form for oral administration. Each sugar-coated tablet contains 2 mg chlorambucil and the inactive ingredients acacia, corn and wheat starch, lactose, magnesium stearate, pharmaceutical glaze, polysorbate 60, sucrose, and talc. Printed with edible black ink.

CLINICAL PHARMACOLOGY: Chlorambucil is rapidly and completely absorbed from the gastrointestinal tract. After single oral doses of 0.6 to 1.2 mg/kg, peak plasma chlorambucil levels are reached within 1 hour and the terminal half-life of the parent drug is estimated at 1.5 hours. Chlorambucil undergoes rapid metabolism to phenylacetic acid mustard, the major metabolite, and the combined chlorambucil and phenylacetic acid mustard urinary excretion is extremely low — less than 1% in 24 hours. The peak plasma levels of chlorambucil and phenylacetic acid mustard are similar, approximating 1 mcg/mL; however, the metabolite's half-life is 1.6 times greater than that of the parent drug.^{2,3}

Chlorambucil and its metabolites are extensively bound to plasma and tissue proteins. In vitro, chlorambucil is 99% bound to plasma proteins, specifically albumin.⁴ Cerebrospinal fluid levels of chlorambucil have not been determined. Evidence of human teratogenicity suggests that the drug crosses the placenta.^{5,6}

Chlorambucil is extensively metabolized in the liver primarily to phenylacetic acid mustard which has antineoplastic activity.^{2,3} Chlorambucil and its major metabolite spontaneously degrade in vivo forming monohydroxy and dihydroxy derivatives.² After a single dose of radiolabeled chlorambucil (¹⁴C), approximately 15% to 60% of the radioactivity appears in the urine after 24 hours. Again, less than 1% of the urinary radioactivity is in the form of chlorambucil or phenylacetic acid mustard.² In summary, the pharmacokinetic data suggest that oral chlorambucil undergoes rapid gastrointestinal absorption and plasma clearance and that it is almost completely metabolized, having extremely low urinary excretion.

INDICATIONS AND USAGE: LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation.

LEUKERAN® (chlorambucil)

CONTRAINDICATIONS: Chlorambucil should not be used in patients whose disease has demonstrated a prior resistance to the agent. Patients who have demonstrated hypersensitivity to chlorambucil should not be given the drug.⁷⁻⁹ There may be cross-hypersensitivity (skin rash) between chlorambucil and other alkylating agents.¹⁰

WARNINGS: Because of its carcinogenic properties, chlorambucil should not be given to patients with conditions other than chronic lymphatic leukemia or malignant lymphomas. Convulsions,¹¹ infertility,¹² leukemia,^{13,14} and secondary malignancies¹⁵ have been observed when chlorambucil was employed in the therapy of malignant and non-malignant diseases.

There are many reports of acute leukemia arising in patients with both malignant¹⁶ and non-malignant¹⁷ diseases following chlorambucil treatment. In many instances, these patients also received other chemotherapeutic agents or some form of radiation therapy. The quantitation of the risk of chlorambucil-induction of leukemia or carcinoma in humans is not possible. Evaluation of published reports of leukemia developing in patients who have received chlorambucil (and other alkylating agents) suggests that the risk of leukemogenesis increases with both chronicity of treatment and large cumulative doses. However, it has proved impossible to define a cumulative dose below which there is no risk of the induction of secondary malignancy. The potential benefits from chlorambucil therapy must be weighed on an individual basis against the possible risk of the induction of a secondary malignancy.

Chlorambucil has been shown to cause chromatid or chromosome damage in humans.^{18,19} Both reversible and permanent sterility have been observed in both sexes receiving chlorambucil.

A high incidence of sterility has been documented when chlorambucil is administered to prepubertal and pubertal males.²⁰ Prolonged or permanent azoospermia has also been observed in adult males.²¹ While most reports of gonadal dysfunction secondary to chlorambucil have related to males, the induction of amenorrhea in females with alkylating agents is well documented and chlorambucil is capable of producing amenorrhea. Autopsy studies of the ovaries from women with malignant lymphoma treated with combination chemotherapy including chlorambucil have shown varying degrees of fibrosis, vasculitis, and depletion of primordial follicles.^{22,23}

Rare instances of skin rash progressing to erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome have been reported.^{8,9} Chlorambucil should be discontinued promptly in patients who develop skin reactions.

Pregnancy: Pregnancy Category D. Chlorambucil can cause fetal harm when administered to a pregnant woman. Unilateral renal agenesis has been observed in two offspring whose mothers received chlorambucil during the first trimester.^{5,6} Urogenital malformations, including absence of a kidney, were found in fetuses of rats given chlorambucil.²⁴ There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

PRECAUTIONS:

General: Many patients develop a slowly progressive lymphopenia during treatment. The lymphocyte count usually rapidly returns to normal levels upon completion of drug therapy. Most patients have some neutropenia after the third week of treatment and this may continue for up to 10 days after the last dose. Subsequently, the neutrophil count usually rapidly returns to normal. Severe neutropenia appears to be related to dosage and usually occurs only in patients who have received a total dosage of 6.5 mg/kg or more in one course of therapy with continuous dosing. About one quarter of all patients receiving the

LEUKERAN® (chlorambucil)

continuous-dose schedule, and one third of those receiving this dosage in 8 weeks or less may be expected to develop severe neutropenia.²⁵

While it is not necessary to discontinue chlorambucil at the first evidence of a fall in neutrophil count, it must be remembered that the fall may continue for 10 days after the last dose, and that as the total dose approaches 6.5 mg/kg, there is a risk of causing irreversible bone marrow damage. The dose of chlorambucil should be decreased if leukocyte or platelet counts fall below normal values and should be discontinued for more severe depression.

Chlorambucil should **not** be given at full dosages before 4 weeks after a full course of radiation therapy or chemotherapy because of the vulnerability of the bone marrow to damage under these conditions. If the pretherapy leukocyte or platelet counts are depressed from bone marrow disease process prior to institution of therapy, the treatment should be instituted at a reduced dosage.

Persistently low neutrophil and platelet counts or peripheral lymphocytosis suggest bone marrow infiltration. If confirmed by bone marrow examination, the daily dosage of chlorambucil should not exceed 0.1 mg/kg. Chlorambucil appears to be relatively free from gastrointestinal side effects or other evidence of toxicity apart from the bone marrow depressant action. In humans, single oral doses of 20 mg or more may produce nausea and vomiting.

Children with nephrotic syndrome¹¹ and patients receiving high pulse doses of chlorambucil²⁶ may have an increased risk of seizures. As with any potentially epileptogenic drug, caution should be exercised when administering chlorambucil to patients with a history of seizure disorder or head trauma, or who are receiving other potentially epileptogenic drugs.

Information for Patients: Patients should be informed that the major toxicities of chlorambucil are related to hypersensitivity, drug fever, myelosuppression, hepatotoxicity, infertility, seizures, gastrointestinal toxicity, and secondary malignancies. Patients should never be allowed to take the drug without medical supervision and should consult their physician if they experience skin rash, bleeding, fever, jaundice, persistent cough, seizures, nausea, vomiting, amenorrhea, or unusual lumps/masses. Women of childbearing potential should be advised to avoid becoming pregnant.

Laboratory Tests: Patients must be followed carefully to avoid life-endangering damage to the bone marrow during treatment. Weekly examination of the blood should be made to determine hemoglobin levels, total and differential leukocyte counts, and quantitative platelet counts. Also, during the first 3 to 6 weeks of therapy, it is recommended that white blood cell counts be made 3 or 4 days after each of the weekly complete blood counts. Galton et al²⁵ have suggested that in following patients it is helpful to plot the blood counts on a chart at the same time that body weight, temperature, spleen size, etc., are recorded. It is considered dangerous to allow a patient to go more than 2 weeks without hematological and clinical examination during treatment.

Drug Interactions: There are no known drug/drug interactions with chlorambucil.

Carcinogenesis, Mutagenesis, Impairment of Fertility: See WARNINGS section for information on carcinogenesis, mutagenesis, and impairment of fertility.

Pregnancy: Teratogenic Effects: Pregnancy Category D: See WARNINGS section.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from chlorambucil, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: The safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS:

LEUKERAN® (chlorambucil)

Hematologic: The most common side effect is bone marrow suppression.²⁷ Although bone marrow suppression frequently occurs, it is usually reversible if the chlorambucil is withdrawn early enough. However, irreversible bone marrow failure has been reported.^{28,29}

Gastrointestinal: Gastrointestinal disturbances such as nausea and vomiting, diarrhea, and oral ulceration occur infrequently.

CNS: Tremors, muscular twitching, myoclonia, confusion, agitation, ataxia, flaccid paresis, and hallucinations have been reported as rare adverse experiences to chlorambucil which resolve upon discontinuation of drug. Rare, focal and/or generalized seizures have been reported to occur in both children^{11,30,31} and adults^{26,32-35} at both therapeutic daily doses and pulse-dosing regimens, and in acute overdose (see PRECAUTIONS: General).

Dermatologic: Allergic reactions such as urticaria and angioneurotic edema have been reported following initial or subsequent dosing. Skin hypersensitivity (including rare reports of skin rash progressing to erythema multiforme,⁹ toxic epidermal necrolysis,⁸ and Stevens-Johnson syndrome) has been reported (see WARNINGS).

Miscellaneous: Other reported adverse reactions include: pulmonary fibrosis, hepatotoxicity and jaundice, drug fever, peripheral neuropathy, interstitial pneumonia, sterile cystitis, infertility, leukemia, and secondary malignancies (see WARNINGS).

OVERDOSAGE: Reversible pancytopenia was the main finding of inadvertent overdoses of chlorambucil.^{36,37} Neurological toxicity ranging from agitated behavior and ataxia to multiple grand mal seizures has also occurred.^{30,36} As there is no known antidote, the blood picture should be closely monitored and general supportive measures should be instituted, together with appropriate blood transfusions, if necessary. Chlorambucil is not dialyzable.

Oral LD₅₀ single doses in mice are 123 mg/kg. In rats, a single intraperitoneal dose of 12.5 mg/kg of chlorambucil produces typical nitrogen-mustard effects; these include atrophy of the intestinal mucous membrane and lymphoid tissues, severe lymphopenia becoming maximal in 4 days, anemia, and thrombocytopenia. After this dose, the animals begin to recover within 3 days and appear normal in about a week, although the bone marrow may not become completely normal for about 3 weeks. An intraperitoneal dose of 18.5 mg/kg kills about 50% of the rats with development of convulsions. As much as 50 mg/kg has been given orally to rats as a single dose, with recovery. Such a dose causes bradycardia, excessive salivation, hematuria, convulsions, and respiratory dysfunction.

DOSAGE AND ADMINISTRATION: The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient. The entire daily dose may be given at one time. These dosages are for initiation of therapy or for short courses of treatment. The dosage must be carefully adjusted according to the response of the patient and must be reduced as soon as there is an abrupt fall in the white blood cell count. Patients with Hodgkin's disease usually require 0.2 mg/kg daily, whereas patients with other lymphomas or chronic lymphocytic leukemia usually require only 0.1 mg/kg daily. When lymphocytic infiltration of the bone marrow is present, or when the bone marrow is hypoplastic, the daily dose should not exceed 0.1 mg/kg (about 6 mg for the average patient).

Alternate schedules for the treatment of chronic lymphocytic leukemia employing intermittent, biweekly, or once-monthly pulse doses of chlorambucil have been reported.^{38,39} Intermittent schedules of chlorambucil begin with an initial single dose of 0.4 mg/kg. Doses are generally increased by 0.1 mg/kg until control of lymphocytosis or toxicity is observed. Subsequent doses are modified to produce mild hematologic toxicity. It is felt that the response rate of chronic lymphocytic leukemia to the biweekly or once-monthly schedule of

LEUKERAN® (chlorambucil)

chlorambucil administration is similar or better to that previously reported with daily administration and that hematologic toxicity was less than or equal to that encountered in studies using daily chlorambucil.

Radiation and cytotoxic drugs render the bone marrow more vulnerable to damage, and chlorambucil should be used with particular caution within 4 weeks of a full course of radiation therapy or chemotherapy. However, small doses of palliative radiation over isolated foci remote from the bone marrow will not usually depress the neutrophil and platelet count. In these cases chlorambucil may be given in the customary dosage.

It is presently felt that short courses of treatment are safer than continuous maintenance therapy, although both methods have been effective. It must be recognized that continuous therapy may give the appearance of "maintenance" in patients who are actually in remission and have no immediate need for further drug. If maintenance dosage is used, it should not exceed 0.1 mg/kg daily and may well be as low as 0.03 mg/kg daily. A typical maintenance dose is 2 mg to 4 mg daily, or less, depending on the status of the blood counts. It may, therefore, be desirable to withdraw the drug after maximal control has been achieved, since intermittent therapy reinstituted at time of relapse may be as effective as continuous treatment.

Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.⁴⁰⁻⁴⁶

There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

HOW SUPPLIED:

White sugar-coated tablet containing 2 mg chlorambucil and printed with "635"; bottle of 50 (NDC 0173-0635-35).

Store at 15° to 25°C (59° to 77°F) in a dry place.

REFERENCES:

1. Everett JL, Roberts JJ, Ross WCJ. Aryl-2-halogenoalkylamines. Pt. XII. Some carboxylic derivatives of NN-Di-2-chloroethylaniline. *J Chem Soc.* 1953;3:2386-2392.
2. Alberts DS, Chang SY, Chen H-SG, Larcom BJ, Jones SE. Pharmacokinetics and metabolism of chlorambucil in man. *Cancer Treat Rev.* 1979;6(suppl):9-17.
3. McLean A, Woods RL, Catovsky D, Farmer P. Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease. *Cancer Treat Rev.* 1979;6(suppl):33-42.
4. Ehrsson H, Lönroth U, Wallin I, Ehrnebo M, Nilsson SO. Degradation of chlorambucil in aqueous solution: influence of human albumin binding. *J Pharm Pharmacol.* 1981;33:313-315. Communications.
5. Shotton D, Monie IW. Possible teratogenic effect of chlorambucil on a human fetus. *JAMA.* 1963;186:74-75.
6. Steege JF, Caldwell DS. Renal agenesis after first trimester exposure to chlorambucil. *South Med J.* 1980;73:1414-1415.
7. Knisley RE, Settipane GA, Albala MM. Unusual reaction to chlorambucil in a patient with chronic lymphocytic leukemia. *Arch Dermatol.* 1971;104:77-79.
8. Pietrantonio F, Moriconi L, Torino F, Romano A, Gangovich A. Unusual reaction to chlorambucil: a case report. *Cancer Lett.* 1990;54:109-111.
9. Hitchins RN, Hocker GA, Thomson DB. Chlorambucil allergy—a series of three cases. *Aust NZ J Med.* 1987;17:600-602.
10. Weiss RB, Bruno S: Hypersensitivity reactions to cancer chemotherapeutic agents. *Ann Intern Med.* 1981;94:66-72.

LEUKERAN® (chlorambucil)

11. Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. *J Pediatr*. 1978;93:516-518.
12. Freckman HA, Fry HL, Mendez FL, Maurer ER. Chlorambucil-prednisolone therapy for disseminated breast carcinoma. *JAMA*. 1964;189:23-26.
13. Aymard JP, Frustin J, Witz F, Colomb JN, Lederlin P, Herbeuval R. Acute leukemia after prolonged chlorambucil treatment for non-malignant disease: a report of a new case and literature survey. *Acta Haematol (Basel)*. 1980;63:283-285.
14. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. *N Engl J Med*. 1981;304:441-447.
15. Lerner HJ. Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. *Cancer Treat Rep*. 1978;62:1135-1138.
16. Zarrabi MH, Grünwald HW, Rosner F. Chronic lymphocytic leukemia terminating in acute leukemia. *Arch Intern Med*. 1977;137:1059-1064.
17. Cameron S. Chlorambucil and leukemia. *N Eng J Med*. 1977;296:1065.
18. Lawler SD, Lele KP. Chromosomal damage induced by chlorambucil in chronic lymphocytic leukemia. *Scand J Haematol*. 1972;9:603-612.
19. Stevenson AC, Patel C. Effects of chlorambucil on human chromosomes. *Mutat Res*. 1973;18:333-351.
20. Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. *J Pediatr*. 1978;92:299-303.
21. Richter P, Calamera JC, Morgenfeld MC, Kierszenbaum AL, Lavieri JC, Mancini RE. Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. *Cancer*. 1970;25:1026-1030.
22. Morgenfeld MC, Goldberg V, Parisier H, Bugnard SC, Bur GE. Ovarian lesions due to cytostatic agents during the treatment of Hodgkin's disease. *Surg Gynecol Obstet*. 1972;134:826-828.
23. Sobrinho LG, Levine RA, DeConti RC. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. *Am J Obstet Gynecol*. 1971;109:135-139.
24. Monie IW. Chlorambucil-induced abnormalities of the urogenital system of rat fetuses. *Anat Rec*. 1961;139:145-153.
25. Galton DAG, Israels LG, Nabarro JDN, Till M. Clinical trials of p-(DI-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma. *Br Med J*. 1955;2:1172-1176.
26. Ciobanu N, Runowicz C, Gucalp R, et al. Reversible central nervous system toxicity associated with high-dose chlorambucil in autologous bone marrow transplantation for ovarian carcinoma. *Cancer Treat Rep*. 1987;71:1324-1325.
27. Moore GE, Bross ID, Ausman R, et al. Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer. Eastern Clinical Drug Evaluation Program. *Cancer Chemother Rep*. 1968;52 (pt 1):661-666.
28. Galton DA, Wiltshaw E, Szur L, Dacie JV. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukemia. *Br J Haematol*. 1961;7:73-98.
29. Rudd P, Fries JF, Epstein WV. Irreversible bone marrow failure with chlorambucil. *J Rheumatol*. 1975;2:421-429.
30. Wolfson S, Olney MB. Accidental ingestion of a toxic dose of chlorambucil: report of a case in a child. *JAMA*. 1957;165:239-240.
31. Byrne TN, Moseley TAE, Finer MA. Myoclonic seizures following chlorambucil overdose. *Ann Neurol*. 1981;9:191-194.
32. LaDelfa I, Bayer N, Myers R, Hoffstein V. Chlorambucil-induced myoclonic seizures in an adult. *J Clin Oncol*. 1985;3:1691-1692.
33. Naysmith A, Robson RH. Focal fits during chlorambucil therapy. *Postgrad Med J*. 1979;55:806-807.

LEUKERAN® (chlorambucil)

34. Blank DW, Nanji AA, Schreiber DH, Hudman C, Sanders HD. Acute renal failure and seizures associated with chlorambucil overdose. *J Toxicol Clin Toxicol*. 1983;20:361-365.
35. Ammenti A, Reitter B, Muller-Wiefel DE. Chlorambucil neurotoxicity: report of two cases. *Helv Paediatr Acta*. 1980;35:281-287.
36. Green AA, Naiman JL. Chlorambucil poisoning. *Am J Dis Child*. 1968;116:190-191.
37. Enck RE, Bennett JM. Inadvertent chlorambucil overdose in adults. *NY State J Med*. 1977;77:1480-1481.
38. Knospe WH, Loeb V Jr, Huguley CM. Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. *Cancer*. 1974;33:555-562.
39. Sawitsky A, Rai KR, Glidewell O, et al. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. *Blood*. 1977;50:1049-1059.
40. Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety; National Institutes of Health; 1983. US Dept of Health and Human Services, Public Health Service publication NIH 83-2621.
41. AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. *JAMA*. 1985;253:1590-1591.
42. National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.
43. Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. *Med J Australia*. 1983;1:426-428.
44. Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. *CA-A Cancer J for Clin*. 1983;33:258-263.
45. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. *Am J Hosp Pharm*. 1990;47:1033-1049.
46. Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines.) *Am J Health-Syst Pharm*. 1996;53:1669-1685.

GlaxoWellcome

Manufactured by
Catalytica Pharmaceuticals, Inc.
Greenville, NC 27834
for Glaxo Wellcome Inc.
Research Triangle Park, NC 27709

©Copyright 1996 Glaxo Wellcome Inc. All rights reserved.

April 2001

RL-924